Impact of provider type on hepatitis c outcomes with boceprevir-based and telaprevir-based regimens

Journal of Clinical Gastroenterology

Volumn 49, Issue 4, 2015, Pages 329-335

  Backus, Lisa I ^a   Belperio, Pamela S ^a   Shahoumian, Troy A ^a   Mole, Larry A ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Direct acting antiviral; Nonphysician provider; Sustained virologic response

Indexed keywords

ANTIANEMIC AGENT; BOCEPREVIR; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MIDDLE AGED; NEUTROPENIA; NURSE PRACTITIONER; OUTCOME ASSESSMENT; PHARMACIST; PHYSICIAN; PHYSICIAN ASSISTANT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; DRUG EFFECTS; GENETICS; GENOTYPE; HEALTH CARE PERSONNEL; HEMATOLOGIC DISEASES; HEPACIVIRUS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VETERAN; VIRUS LOAD;

ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GENOTYPE; HEALTH PERSONNEL; HEMATOLOGIC DISEASES; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VETERANS; VIRAL LOAD;

EID: 84928359494     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000124     Document Type: Article

References (38)

1. Mitchell AE, Colvin HM, Beasley RP. The Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51:729-733.
2. Smith BD, Morgan RL, Beckett GA, et al. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
3. Moyer VA, On behalf of the US Preventative Services Task Force. Screening for hepatitis C virus infection in adults: US Preventative Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-357.
4. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-1887.
5. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13:401-408.
6. Fried M, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918-1929.
7. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2013;146:430-441.
8. Backus LI, Belperio PS, Loomis TP, et al. Hepatitis C virus screening and prevalence among US veterans in department of veterans affairs care. JAMA Intern Med. 2013;173:1549-1552.
9. Chan K, Lai MN, Groessl EJ, et al. Cost-effectiveness analysis of direct-acting antiviral therapy for treatment-naive patients with chronic hepatitis C genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol. 2013;11: 1503-1510.
10. Fineberg HV. Shattuck Lecture. A successful and sustainable health system-how to get there from here. N Engl J Med. 2012;366:1020-1027.
11. Morgan PA, Abbott DH, McNeil RB, et al. Characteristics of primary care office visits to nurse practitioners, physician assistants and physicians in United States Veterans Health Administration facilities, 2005 to 2010: a retrospective cross-sectional analysis. Hum Resour Health. 2012;10:42-50.
12. National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0; Published: May 28, 2009 (v4.03: June 14, 2010). Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5 x 7.pdf. Accessed August 10, 2013.
13. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32-36.
14. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11: 561-570.
15. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560.
16. Hernan M, Robins J. Casual Inference. Boca Raton, FL: Chapman & Hall/CRC; 2013. Available at: http://www.hsph. harvard.edu/miguel-hernan/causal-inference-book/. Accessed May 1, 2013.
17. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
18. Jacobson IM, Mc Hutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
19. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217.
20. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417-2428.
21. Olson M, Jacobson IM. Role of the nurse practitioner in the management of patients with chronic hepatitis C. J Am Acad Nurse Pract. 2011;23:410-420.
22. Shutt JD, Robathan J, Vyas SK. Impact of a clinical nurse specialist on the treatment of chronic hepatitis C. Br J Nurs. 2008;17:572-575.
23. Smith JP. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Pharmacotherapy. 2008;28:1151-1161.
24. Kolor B. Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. Pharmacotherapy. 2005;25:1230-1241.
25. Smith JP, Dong MH, Kaunitz JD. Evaluation of a pharmacist-managed hepatitis C care clinic. Am J Health-Syst Pharm. 2007;64:632-636.
26. Marino EL, Alvarez-Rubio L, Miro S, et al. Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C. J Manag Care Pharm. 2009;15:147-150.
27. Hydes T, Allen H, Al-Shamma S, et al. District general hospital networks can provide safe and effective hepatitis C treatment: results of a 5-year audit. Eur J Gastroenterol Hepatol. 2013;25:942-947.
28. Mundinger MO, Kane RL, Lenz ER, et al. Primary care outcomes in patients treated by nurse practitioners or physicians. JAMA. 2000;283:59-68.
29. Ohman-Strickland PA, Orzano AJ, Hudson SV, et al. Quality of diabetes care in family medicine practices: influence of nurse-practitioners and physician's assistants. Ann Fam Med. 2008;6:14-22.
30. Kuethe MC, Vaessen-Verberne AA, Elbers RG, et al. Nurse versus physician-led care for the management of asthma. Cochrane Database Syst Rev. 2013;2:CD009296.
31. Newhouse RP, Stanik-Hutt J, White KM, et al. Advanced practice nurse outcomes 1990-2008: a systematic review. Nurs Econ. 2011;29:230-250.
32. Health Quality Ontario. Specialized nursing practice for chronic disease management in the primary-care setting: an evidence-based analysis. Ont Health Technol Assess Ser. 2013;13:1-66. Available from: http://www.hqontario.ca/Portals/0/Documents/eds/ohtas/full-report-specialized-nursing-practice-cdm-130906-en.pdf.
33. Nkansah N, Mostovetsky O, Yu C, et al. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev. 2010;7: CD000336.
34. Scott DM, Boyd ST, Stephan M, et al. Outcomes of pharmacist managed diabetes care services in a community health center. Am J Health Syst Pharm. 2006;63:2116-2122.
35. Giberson S, Yoder S, Lee MP. Improving patient and health system outcomes through advanced pharmacy practice. A report to the US Surgeon General. Office of the Chief Pharmacist. US Public Health Service. 2011.
36. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199-2207.
37. McGovern BH. Hepatitis C virus and the infectious disease physician: a perfect match. Clin Infect Dis. 2012;55:414-417.
38. Torres HA, Adachi JA, Roach LR, et al. Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: help is on the way. Clin Infect Dis. 2012;54: 740-742.